Zydus Wellness' Q3 FY 2025-26 Quarterly Results
- 04 Feb 2026
Result Summary
- Zydus Wellness Ltd reported a 48.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 107.4%.
- Its expenses for the quarter were up by 49.7% QoQ and 119.6% YoY.
- The net profit decreased 24.4% QoQ and decreased 723.4% YoY.
- The earnings per share (EPS) of Zydus Wellness Ltd declined at 1.25 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 965.70 | 651.90 | 465.70 | 48.1% | 107.4% |
Total Expenses | 1000.60 | 668.30 | 455.60 | 49.7% | 119.6% |
Profit Before Tax | -41.50 | -50.60 | 10.10 | -18.0% | -510.9% |
Tax | -1.60 | 2.20 | 3.70 | -172.7% | -143.2% |
Profit After Tax | -39.90 | -52.80 | 6.40 | -24.4% | -723.4% |
Earnings Per Share | -1.25 | -1.66 | 1.01 | -24.7% | -223.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zydus Wellness Ltd is a company operating within the health and wellness sector, primarily known for its range of consumer products focused on health, nutrition, and wellness. The company offers a diverse portfolio that includes sugar substitutes, skincare products, and other health-related consumer goods. Key products under its umbrella include brands like Sugar Free, EverYuth, and Nutralite, which are well-entrenched in the Indian market. Zydus Wellness has been part of the evolving health and wellness industry in India, which has seen substantial growth driven by increasing health consciousness among consumers. Recent developments in the company include the expansion of its product lines and a focus on broadening its market reach through innovative product offerings.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Zydus Wellness Ltd reported a total income of ₹965.70 crores. This represents a significant increase compared to ₹651.90 crores in the second quarter of the same fiscal year (Q2FY26), marking a quarter-over-quarter (QoQ) growth of 48.1%. When compared to the same quarter of the previous fiscal year (Q3FY25), where the total income was ₹465.70 crores, there was a remarkable year-over-year (YoY) growth of 107.4%. This considerable rise in revenue indicates a robust top-line performance relative to both the previous quarter and the same period in the prior fiscal year.
Profitability
The profitability metrics for Zydus Wellness Ltd in Q3FY26 reflect a challenging period. The company reported a profit before tax (PBT) of -₹41.50 crores, which is an improvement from the -₹50.60 crores registered in Q2FY26, showing an 18.0% QoQ improvement. However, compared to Q3FY25, where the PBT was a positive ₹10.10 crores, this represents a substantial decline of 510.9% YoY. The profit after tax (PAT) for Q3FY26 stood at -₹39.90 crores, again an improvement from the -₹52.80 crores in Q2FY26, reflecting a 24.4% QoQ improvement. However, it marks a significant drop from the ₹6.40 crores reported in Q3FY25, a 723.4% YoY decrease. The earnings per share (EPS) also followed a similar trend, with -₹1.25 in Q3FY26 compared to -₹1.66 in Q2FY26 and ₹1.01 in Q3FY25, indicating a 24.7% QoQ improvement but a 223.8% YoY decline.
Operating Metrics
The operational efficiency of Zydus Wellness Ltd as reflected in its total expenses for Q3FY26 amounted to ₹1000.60 crores, which increased from ₹668.30 crores in Q2FY26, indicating a 49.7% QoQ rise. Compared to Q3FY25, where total expenses were ₹455.60 crores, there was a 119.6% YoY increase. The financial data suggests that while the company has achieved significant revenue growth, there has been a corresponding increase in expenses, which impacts overall profitability. The tax component for Q3FY26 was -₹1.60 crores, a considerable change from ₹2.20 crores in Q2FY26 and ₹3.70 crores in Q3FY25, reflecting a decrease of 172.7% QoQ and 143.2% YoY. These figures highlight the financial dynamics at play in Zydus Wellness's quarterly performance.